verapamil has been researched along with simvastatin in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Kantola, T; Kivistö, KT; Neuvonen, PJ | 1 |
| Dobrinska, M; Gruer, PJ; Tobert, JA; Vega, JM | 1 |
| Dreisbach, AW; Kusus, M; Lertora, JJ; Simon, EE; Stapleton, DD | 1 |
| Yeo, KR; Yeo, WW | 1 |
| Cheng, G; Huang, J; Ma, J; Shan, J; Xu, G; Ying, S; Zhu, L | 1 |
| Jacobson, TA | 1 |
| Baciewicz, AM; Chrisman, CR; Finch, CK; Self, TH | 1 |
| Liu, L; Liu, X; Sai, Y; Wang, D; Wang, J; Xia, S; Xue, W | 1 |
| Alizadeh, AM; Aminolsharieh Najafi, S; Khori, V; Moheimani, HR; Nayebpour, M; Shakiba, D; Zahedi, M | 1 |
| Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J | 1 |
| Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C | 1 |
2 review(s) available for verapamil and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Update on rifampin, rifabutin, and rifapentine drug interactions.
Topics: Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Contraceptives, Oral; Cytochrome P-450 Enzyme System; Digoxin; Drug Interactions; HIV Protease Inhibitors; Humans; Itraconazole; Rifabutin; Rifampin; Simvastatin; Verapamil | 2013 |
2 trial(s) available for verapamil and simvastatin
| Article | Year |
|---|---|
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
Topics: Adult; Anti-Bacterial Agents; Calcium Channel Blockers; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Erythromycin; Female; Humans; Hypolipidemic Agents; Male; Mixed Function Oxygenases; Reference Values; Simvastatin; Verapamil | 1998 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
24 other study(ies) available for verapamil and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Calcium channel blocker-simvastatin interaction.
Topics: Calcium Channel Blockers; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscles; Simvastatin; Verapamil | 1999 |
Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.
Topics: Acute Kidney Injury; Anti-Arrhythmia Agents; Cyclosporine; Digoxin; Drug Interactions; Enzyme Inhibitors; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Middle Aged; Rhabdomyolysis; Simvastatin; Verapamil | 2000 |
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
Topics: Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microsomes, Liver; Simvastatin; Verapamil | 2001 |
Apoptosis induced by simvastatin in rat vascular smooth muscle cell through Ca2+-calpain and caspase-3 dependent pathway.
Topics: Acrylates; Animals; Apoptosis; Blotting, Western; Calcium; Calpain; Caspase 3; Caspases; Enzyme Activation; Flow Cytometry; Muscle, Smooth, Vascular; Rats; Rats, Sprague-Dawley; Signal Transduction; Simvastatin; Thapsigargin; Verapamil | 2003 |
A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Topics: Calcium Channel Blockers; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Gastric Mucosa; Humans; Intestine, Small; Liver; Microsomes, Liver; Midazolam; Models, Biological; Simvastatin; Stereoisomerism; Verapamil | 2013 |
Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit.
Topics: Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; Brugada Syndrome; Cardiac Conduction System Disease; Electrocardiography; Heart Conduction System; Heart Rate; Male; Rabbits; Simvastatin; Tachycardia; Tachycardia, Atrioventricular Nodal Reentry; Verapamil | 2015 |
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Drug Incompatibility; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Biological; Simvastatin; Verapamil; Young Adult | 2014 |
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Topics: Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Verapamil | 2020 |